Echo IQ Limited announced that it recently learned of sensitive information concerning its application process with the American Medical Association. The company had applied for a Category III CPT code to secure reimbursement for its EchoSolv AS technology, which is used for noninvasive evaluation of aortic stenosis through advanced analysis of echocardiogram measurements. However, on 17 May 2025, a letter from the CPT Editorial Panel indicated that the application did not meet two of the general criteria required for Category I or Category III coding. Echo IQ Limited has now committed to addressing the deficiencies noted by the panel and plans to resubmit its revised application by the 11 June 2025 deadline in order to be considered at the upcoming September 2025 meeting. In response to this development and the subsequent trading activity, the company confirmed that it had promptly requested a trading halt when it realized the market could be reacting to this unannounced information. Trading activity earlier in the day reflected significant volatility, with the share price moving from a high of $0.32 to a low of $0.28, and a marked increase in volume that prompted inquiries from the market regulator. The company reassured investors that its internal review process is in full compliance with mandatory disclosure requirements and that revising the application is underway with support from its executive team in the United States. The news presents mixed sentiments for investors. On the bullish side, Echo IQ Limited’s proactive approach in revising its submission and setting clear deadlines for resubmission shows determination to secure regulatory approval, which could unlock future revenue through reimbursement for its innovative technology. Conversely, the bearish view is supported by the initial rejection of the application and the pronounced market volatility, which might signal caution among beginner traders until further regulatory validation is received.